Trials / Completed
CompletedNCT01133704
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Dendreon · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | sipuleucel-T | |
| BIOLOGICAL | APC-Placebo |
Timeline
- Start date
- 2000-05-01
- Primary completion
- 2003-03-01
- Completion
- 2005-05-01
- First posted
- 2010-05-31
- Last updated
- 2010-09-08
- Results posted
- 2010-09-02
Source: ClinicalTrials.gov record NCT01133704. Inclusion in this directory is not an endorsement.